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Overall there is a potential for better results even due to conventional 
chemotherapy giving new cytotoxics or selecting patients and treatment 
by pharmacogenomic data.
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Lung cancer results in more than a million deaths annually worldwide 
(1). Non-small cell lung cancer, which comprises of adenocarcinoma, 
squamous cell carcinoma, bronchioloalveolar carcinoma (BAC) and 
large cell carcinoma, accounts for more than 80% of all cases of lung 
cancer. NSCLC is diagnosed at an advanced stage in a majority of the 
patients, for whom systemic therapy remains the mainstay of treatment. 
Systemic therapy also beneﬁts patients with earlier stages of NSCLC, 
since micrometastasis is an early event (2, 3). The availability of newer 
and novel chemotherapeutic agents has contributed to both the survival 
and quality of life beneﬁts for patients with advanced stage NSCLC (4-
6). However, it appears that an efﬁcacy plateau has been reached with 
currently available agents in both the ﬁrst-line and second-line therapy 
of advanced NSCLC (4, 7). 
Molecularly targeted agents provide the ability to modulate events that 
are unique to the cancer cell. Since NSCLC has wide molecular hetero-
geneity, a number of cell signaling pathways are potential targets for 
treatment (8). The targeted agents that have been actively investigated 
for the treatment of NSCLC include EGFR inhibitors, anti-angiogenic 
agents, proteosomal inhibition, inhibitors of the mammalian target of 
rapamycin (mTOR) pathway, matrix metalloproteinase inhibitors and 
protein kinase C inhibitors. Inhibitors of the EGFR and the anti-an-
giogenic pathway are already used for routine care of patients with 
advanced NSCLC and will be discussed elsewhere. 
Proteosome inhibition
The 26 S proteosome is a multi-subunit protein complex that is in-
volved in the degradation of a variety of proteins with critical functions 
such as regulation of the cell cycle, transcription and apoptosis (9). 
Bortezomib is a speciﬁc inhibitor of the 26 S proteosome that has been 
shown in preclinical models to induce apoptosis and enhance the efﬁca-
cy of chemotherapy against a variety of cancer cell lines. It is approved 
for the treatment of multiple myeloma in the US. Based on promising 
preclinical activity, bortezomib has been evaluated for the treatment 
of advanced NSCLC by multiple clinical trials. In a phase II study, ad-
vanced NSCLC patients (N=155) who progressed following one prior 
chemotherapy regimen were randomized to treatment with bortezomib 
alone or in combination with docetaxel (10). The response rate was 8% 
with bortezomib monotherapy compared to 9% with the combination. 
However the median time to progression favored the combination (4 
months vs. 1.5 months). In another phase II study by the SWOG, bort-
ezomib was combined with the regimen of carboplatin and gemcitabine 
for ﬁrst line therapy of advanced NSCLC patients (N=121) (11). The 
combination was tolerated well and was associated with a median 
survival of 11 months. The median time to progression was 5 months. 
Main toxicities associated with the combination included thrombocyto-
penia, neutropenia and neuropathy. Bortezomib has also been evaluated 
in combination with other targeted agents such as EGFR inhibitors by 
preclinical studies. Favorable results have led to early phase clinical tri-
als with novel bortezomib-based combinations. Based on these results, 
bortezomib appears to be an active agent for the treatment of advanced 
NSCLC. Large randomized clinical trials are necessary to determine 
whether the addition of bortezomib to chemotherapy would result in 
improvements in survival for patients with advanced NSCLC.
Histone deacetylase (HDAC) inhibitors
HDAC mediates the transcription of a number of genes relevant for cell 
cycle regulation and apoptosis. By altering the dynamic equilibrium 
between histone acetylation and deacetylation, HDAC inhibitors have 
been noted to exert anti-cancer effects against a variety of cancer cell 
lines (12). The anti-cancer activity of HDAC inhibitors has also been 
attributed to the effects on non-histone targets such as p53, heat shock 
protein 90, alpha tubulin, etc. A number of novel agents that inhibit 
HDAC are currently under development.
Vorinostat (SAHA) is an orally administered inhibitor of HDAC that 
has recently been approved for the treatment of refractory cutaneous 
T-cell lymphoma. Early phase clinical trials with vorinostat have dem-
onstrated activity against mesothelioma and non-small cell lung cancer 
(13). Vorinostat also enhances the activity of other commonly used 
anti-cancer agents such as the platinum compounds and the taxanes 
(14, 15). Therefore, we conducted a phase I study to evaluate the com-
bination of vorinostat with carboplatin and paclitaxel (16). The study 
included 19 patients with previously untreated NSCLC. Vorinostat at 
a dose of 400 mg/day (2 weeks on, 1 week off) was combined safely 
with carboplatin (AUC = 6 mg/ml X min) and paclitaxel (200 mg/m2). 
There were 10 objective responses and 4 had disease stabilization 
out of a total of 19 patients with previously untreated NSCLC. These 
exciting results have led to a phase II study that randomizes patients 
with advanced NSCLC to treatment with carboplatin and paclitaxel in 
combination with either vorinostat or placebo. Vorinostat is also being 
evaluated in combination with a number of targeted agents such as 
EGFR inhibitors. In particular, vorinostat has been shown to have syn-
ergistic interactions with EGFR TKI in resistant cell lines by its effects 
on E-cadherin (17). Therefore, a phase I/II study is being conducted 
to evaluate vorinostat in combination with erlotinib for second line 
treatment of advanced NSCLC. Several other HDAC inhibitors such as 
PXD 101, MS 275 and LBH 589 are also in early phase clinical trials 
for advanced NSCLC. 
mTOR pathway
The mammalian target of rapamycin (mTOR) is a 289 kD serine/threo-
nine kinase, that plays a central role in regulating cell growth, prolifera-
tion and survival (18). mTOR functions downstream of the PI3K/Akt 
pathway which is a major cell survival pathway (19). mTOR is 
dysregulated in several malignancies and has therefore become a target 
for the treatment of cancer. Agents such as CCI-779 (temsirolimus) 
and RAD 001(everolimus) are in various stages of clinical evaluation 
for the treatment of various malignancies. A phase III study conducted 
for patients with advanced renal cell carcinoma demonstrated survival 
advantage for high-risk patients treated with CCI-779 over therapy 
with interferon (20). This has paved the way for extensive evaluation 
of mTOR inhibitors as monotherapy or in combination with established 
agents for the treatment of various malignancies.
In lung cancer, the mTOR inhibitors are under evaluation as mono-
therapy and in combination with proven agents. A phase I/II study 
is evaluating the combination of erlotinib and RAD 001 for patients 
with refractory NSCLC (21). Preliminary results indicated promising 
anti-cancer activity, though the optimal doses are yet to be established 
for the combination. Another ongoing study is evaluating the combi-
nation of geﬁtinib and RAD 001 for advanced NSCLC in the second 
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or third line therapy settings. A phase IB study is evaluating the use 
of RAD 001 as pre-operative therapy for a brief duration followed by 
surgical resection with the intent of evaluating the molecular effects 
of this novel agent within the tumor of early stage NSCLC patients. 
The results of such studies will provide insight into the role of mTOR 
inhibitors in lung cancer therapy.
Conclusions
In addition to the agents discussed in this review, a number of agents 
that modulate other pathways including MEK, aurora kinase, C-met 
and insulin-like growth factor, are being studied for the treatment of 
various solid malignancies including NSCLC (24-27). As these agents 
enter the clinic, proper patient selection will be critical to their success. 
Clinical or molecular predictive markers that will help with patient 
selection should be evaluated as part of early phase clinical trials. With 
the increasing number of available new agents, enhancing accrual to 
clinical trials will be critical to successfully test these agents in a timely 
manner. 
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Despite incremental gains improving both the quality and length of life 
of persons with lung cancer, cure remains elusive for nearly all patients 
with metastases. The need for better treatments has never been greater. 
To meet this challenge, advances in biology and biotechnology have 
provided us with hundreds of agents appropriate for testing in patients. 
This opportunity has brought with it the challenge to select and quickly 
assess which of these potential treatments will further improve the lives 
of patients with lung cancer and maybe even affect a cure. Despite the 
importance and enormity of this task, relatively little attention has been 
paid to the process of developing therapies to combat lung cancer. 
In 1949, Karnofsky and Burchenal observed that agents that do not 
objectively shrink tumors cannot be expected to prolong life. Half a 
century of drug development has proven this assertion correct. This 
is especially true with therapies that lead to cure or dramatic beneﬁt. 
No randomized trials were necessary to prove that etoposide was a 
useful treatment in SCLC. Today, our best surrogate for survival or 
cure remains the objective documentation of the regression of tumors 
on physical exam or imaging studies. Our task is to identify how to 
document changes in lesion size more accurately and quickly. With 
rare exception, the helical CT scan is the optimal way to achieve this 
goal. It is likely that uni- or bi-dimensional CT measurements are 
reliable and reproducible within 10% or less based on a study now 
underway. Where this has been studied with both single agent geﬁtinib 
and bevacizumab, changes in lesion size exceeding this threshold can 
be documented in as little as 14 or 21 days. These facts suggest at our 
current technology allows us to replace current response standards of 
demanding 30% or 50% changes to deﬁne beneﬁt and the necessity to 
